| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Lutz Tautz | Q56501559 |
| Yotis A Senis | Q60484604 | ||
| P2093 | author name string | Souad Rahmouni | |
| Cécile Oury | |||
| P2860 | cites work | Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase | Q24292364 |
| Src kinase activation by direct interaction with the integrin β cytoplasmic domain | Q24298960 | ||
| The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer | Q24314853 | ||
| Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence | Q24316042 | ||
| Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR | Q24316477 | ||
| PTP-1B is an essential positive regulator of platelet integrin signaling | Q24317102 | ||
| Large-scale structural analysis of the classical human protein tyrosine phosphatome | Q24321557 | ||
| Expression cloning of a human dual-specificity phosphatase | Q24562377 | ||
| Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo | Q24669536 | ||
| Platelet signaling | Q26824744 | ||
| Multidentate Small-Molecule Inhibitors of Vaccinia H1-Related (VHR) Phosphatase Decrease Proliferation of Cervix Cancer Cells | Q27658054 | ||
| Development of accessible peptidic tool compounds to study the phosphatase PTP1B in intact cells | Q27688069 | ||
| Extracellular regulated kinases (ERK) 1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway | Q28142838 | ||
| Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use | Q28263273 | ||
| Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. | Q46612650 | ||
| The Ig-ITIM superfamily member PECAM-1 regulates the "outside-in" signaling properties of integrin alpha(IIb)beta3 in platelets | Q46635894 | ||
| Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation | Q46637396 | ||
| GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism | Q46684669 | ||
| Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene | Q48111435 | ||
| Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. | Q51828070 | ||
| The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion | Q52550457 | ||
| Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. | Q53335960 | ||
| Dominant role of the protein-tyrosine phosphatase CD148 in regulating platelet activation relative to protein-tyrosine phosphatase-1B. | Q54477531 | ||
| Using small molecules to target protein phosphatases | Q57006863 | ||
| Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis | Q61784004 | ||
| The role of ITAM- and ITIM-coupled receptors in platelet activation by collagen | Q63408039 | ||
| Potent Inhibition of Insulin Receptor Dephosphorylation by a Hexamer Peptide Containing the Phosphotyrosyl Mimetic F2Pmp | Q71653894 | ||
| Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene | Q72872607 | ||
| Platelets activated by collagen through immunoreceptor tyrosine-based activation motif play pivotal role in initiation and generation of neointimal hyperplasia after vascular injury | Q77690015 | ||
| Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice | Q83594701 | ||
| Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs | Q84114293 | ||
| CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis | Q84313347 | ||
| Novel antiplatelet drugs in clinical development | Q86496303 | ||
| Protein tyrosine phosphatases in the human genome | Q28265924 | ||
| GPVI and integrin alphaIIb beta3 signaling in platelets | Q28267414 | ||
| Protein tyrosine phosphatases and the immune response | Q28300971 | ||
| The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis | Q28509969 | ||
| Megakaryocyte-specific deletion of the protein-tyrosine phosphatases Shp1 and Shp2 causes abnormal megakaryocyte development, platelet production, and function | Q28587122 | ||
| Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function | Q28592055 | ||
| Protein tyrosine phosphatases: from genes, to function, to disease | Q29614826 | ||
| Ligand efficiency: a useful metric for lead selection | Q29617403 | ||
| Signaling--2000 and beyond | Q29617413 | ||
| Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene | Q29618933 | ||
| DUSP3/VHR is a pro-angiogenic atypical dual-specificity phosphatase | Q30579145 | ||
| Platelet PECAM-1 inhibits thrombus formation in vivo. | Q33223436 | ||
| A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis | Q33239027 | ||
| Strategies for developing protein tyrosine phosphatase inhibitors | Q33285969 | ||
| The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. | Q33384822 | ||
| PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model | Q33392880 | ||
| Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation | Q33394424 | ||
| Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia | Q33401678 | ||
| Targeting integrin and integrin signaling in treating thrombosis | Q33417854 | ||
| Triggers, targets and treatments for thrombosis | Q33765444 | ||
| Targeting the disordered C terminus of PTP1B with an allosteric inhibitor | Q33774262 | ||
| Structural and evolutionary relationships among protein tyrosine phosphatase domains | Q34012560 | ||
| Therapeutic potential of targeting the oncogenic SHP2 phosphatase | Q34061302 | ||
| Calpain-catalyzed cleavage and subcellular relocation of protein phosphotyrosine phosphatase 1B (PTP-1B) in human platelets. | Q34070941 | ||
| Inside the human cancer tyrosine phosphatome | Q34156227 | ||
| Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. | Q34233293 | ||
| Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis | Q34607187 | ||
| Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer | Q34695575 | ||
| Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity | Q34775047 | ||
| Mechanisms of thrombus formation | Q34815800 | ||
| Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2 | Q35001128 | ||
| Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis | Q35102293 | ||
| Syndecan-2 is a novel ligand for the protein tyrosine phosphatase receptor CD148 | Q35241542 | ||
| Critical role for Syk in responses to vascular injury | Q35525691 | ||
| PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase | Q35616065 | ||
| High-throughput screening for protein tyrosine phosphatase activity modulators. | Q42254852 | ||
| Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. | Q42582678 | ||
| Dual-specificity protein tyrosine phosphatase VHR down-regulates c-Jun N-terminal kinase (JNK). | Q42816065 | ||
| CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases. | Q43117437 | ||
| Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial | Q44041122 | ||
| Allosteric inhibition of protein tyrosine phosphatase 1B. | Q44982496 | ||
| Selective detection of allosteric phosphatase inhibitors. | Q46024147 | ||
| Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study | Q46088369 | ||
| Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs | Q46430769 | ||
| Protein phosphorylation in signaling--50 years and counting | Q46541371 | ||
| Thrombospondin-1 acts as a ligand for CD148 tyrosine phosphatase | Q35750930 | ||
| Protein tyrosine phosphatases in T cell physiology. | Q35818873 | ||
| Inhibitors of protein tyrosine phosphatases: next-generation drugs? | Q36131111 | ||
| A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo | Q36370457 | ||
| Targeting the PTPome in human disease | Q36379394 | ||
| Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets | Q36401453 | ||
| The platelet ATP and ADP receptors | Q36412840 | ||
| Protein-tyrosine phosphatases and cancer | Q36430193 | ||
| Recent development of small molecular specific inhibitor of protein tyrosine phosphatase 1B. | Q36622709 | ||
| The SYK tyrosine kinase: a crucial player in diverse biological functions | Q36662082 | ||
| PTP1B as a drug target: recent developments in PTP1B inhibitor discovery | Q36805716 | ||
| The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 | ||
| Protein tyrosine phosphatases in autoimmunity. | Q37096069 | ||
| Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future | Q37310828 | ||
| PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer. | Q37367858 | ||
| KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. | Q37384068 | ||
| Tyrosine phosphorylation: thirty years and counting | Q37408903 | ||
| Antiplatelet therapies for the treatment of cardiovascular disease | Q37684794 | ||
| Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development | Q37855897 | ||
| Novel protein tyrosine phosphatase 1B inhibitors: interaction requirements for improved intracellular efficacy in type 2 diabetes mellitus and obesity control | Q37891190 | ||
| PTP1B and TCPTP--nonredundant phosphatases in insulin signaling and glucose homeostasis | Q37992232 | ||
| Protein tyrosine phosphatases in lymphocyte activation and autoimmunity | Q38003542 | ||
| Platelet GPVI: a target for antithrombotic therapy?! | Q38035484 | ||
| New fundamentals in hemostasis | Q38072904 | ||
| Protein tyrosine phosphatases: structure, function, and implication in human disease. | Q38122079 | ||
| Protein-tyrosine phosphatases: a new frontier in platelet signal transduction | Q38135450 | ||
| Dual-specificity phosphatases as molecular targets for inhibition in human disease | Q38160921 | ||
| Aspirin for prevention and treatment of venous thromboembolism | Q38205516 | ||
| Src family kinases: at the forefront of platelet activation | Q38239258 | ||
| Novel antiplatelet agents in acute coronary syndrome | Q38257119 | ||
| Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention | Q38261370 | ||
| First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers | Q38296268 | ||
| Prodrug delivery of novel PTP1B inhibitors to enhance insulin signalling | Q38354830 | ||
| VHR/DUSP3 phosphatase: structure, function and regulation | Q38372232 | ||
| BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR. | Q40174592 | ||
| Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. | Q40179649 | ||
| Cellular effects of small molecule PTP1B inhibitors on insulin signaling | Q40620572 | ||
| Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. | Q40703161 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2786-2797 | |
| P577 | publication date | 2015-04-04 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry | Q2904200 |
| P1476 | title | Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy | |
| P478 | volume | 23 |
| Q40579483 | Functional Analysis of Protein Tyrosine Phosphatases in Thrombosis and Hemostasis. |
| Q47231597 | Maintenance of murine platelet homeostasis by the kinase Csk and the phosphatase CD148. |
| Q39020269 | Modulation of VEGF receptor 2 signaling by protein phosphatases |
| Q58699207 | Revisiting the roles of VHR/DUSP3 phosphatase in human diseases |
| Q38685836 | The contribution of zinc to platelet behaviour during haemostasis and thrombosis. |
Search more.